DAX+0,08 % EUR/USD-0,11 % Gold-0,27 % Öl (Brent)+3,52 %

NantKwest Chairman & CEO Dr. Patrick Soon-Shiong to Present Vision for Next Generation Natural Killer Cell Therapies During Keynote Address at Innate Killer Summit

Nachrichtenquelle: Business Wire (engl.)
18.03.2019, 10:00  |  278   |   |   

NantKwest (Nasdaq:NK), a leading clinical-stage, natural killer cell based therapeutics company, today announced that the company’s Chairman & CEO, Dr. Patrick Soon-Shiong, will be giving a keynote address at the Innate Killer Summit in San Diego on Wednesday, March 20, 2019.

Dr. Soon-Shiong’s keynote address will provide a vision of next generation NK cell therapies and feature a review of translational R&D activities, state-of-the-art manufacturing requirements, along with clinical progress.

“Over a few short years, the cell therapy industry has made significant progress with remarkable patient responses to therapy being seen in a few select cancer indications. While encouraging, a significant need still exists for the majority of cancer types where existing cell therapies have not been shown to be effective,” said Dr. Soon-Shiong. “Natural killer cells have potent cancer cell killing capabilities, yet are often overlooked as the immune system’s first line of defense against cancer and other foreign invaders. Without question, cancer patients deserve better treatment options and I welcome the opportunity to present my vision for next generation NK cell therapies at the Summit.”

Conference Details:

Date: Wednesday, March 20, 2019
Presentation Title: Charting a Path to Next Generation Natural Killer Cell Immunotherapies
Presenter: Patrick Soon-Shiong, MD, Chairman & CEO
Time: 8:30 a.m. PT

Dr. Soon-Shiong presentation will be posted on the NantKwest website and will be available for 30 days following the Keynote. For more information regarding NantKwest, please visit www.nantkwest.com.

For more event information, please visit: https://innate-killer.com/

About NantKwest

NantKwest, a member of the NantWorks ecosystem of companies, is an innovative clinical-stage immunotherapy company focused on harnessing the power of the innate immune system by using the natural killer cell to treat cancer and virally induced infectious diseases.

NantKwest is uniquely positioned to implement precision cancer medicine, with the potential to change the current paradigm of cancer care. Natural Killer (NK) cells are a safeguard in the human body designed to recognize and detect cells under stress due to cancer or viral infection. NantKwest’s “off-the-shelf” activated NK cell platform is designed to destroy cancer and virally infected cells from the body. The safety of our NK cells as well as their activity against a broad range of cancers has been tested in phase I clinical trials in Canada and Europe as well as in multiple phase I and II clinical trials in the United States. In addition to being a universal cell-based therapy that does not require individualized patient sourcing or matching, our NK cell products have been largely administered in the outpatient setting as an “off-the-shelf” living drug.

With the capacity to grow active killer cells as a living cancer therapy, our NK cells have been designed to induce cell death against cancers and virally infected cells by several mechanisms, including: innate killing, whereby all of our NK platforms recognize the stress proteins typically found on cancer cells, which, upon binding, release toxic granules to immediately kill their targets; antibody-mediated killing with our haNK platform, which are NK cells engineered to express antibody receptors that can bind to therapeutic antibody products, thereby enhancing the cancer cell killing effect of that antibody; and Chimeric Antigen Receptor directed killing using the taNK platform, which includes NK cells engineered to incorporate chimeric antigen receptors (CARs) to target tumor-specific antigens found on the surface of cancer cells. All three modes of killing (innate, antibody-mediated, and CAR directed killing) are employed by our t-haNK platform, which is an innovative combination of our aNK, haNK and taNK platforms in a single product.

Seite 1 von 3
Wertpapier
NantKwest
Mehr zum Thema
Euro


0 Kommentare

Schreibe Deinen Kommentar

Bitte melden Sie sich an, um zu kommentieren. Anmelden | Registrieren

 

Disclaimer

Meistgelesene Nachrichten des Autors

Titel
Titel
Titel
Titel
Aus der Redaktion